Pertuzumab - novyy vzglyad na HER2-polozhitel'nyy metastaticheskiy rak molochnoy zhelezy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

However, there is obvious fact that not all patients with HER2-positive respond to trastuzumab-containing therapy. The use of combination of pertuzumab, trastazumab and docetaxel in the first-line therapy of metastatic breast cancer has allowed to significantly increase the effectiveness of treatment. The CLEOPATRA study showed an unprecedented increase in overall survival of patients receiving combination of pertuzumab, trastuzumab and docetaxel as first-line treatment compared with the group receiving placebo, trastuzumab, and docetaxel (56.5 months vs 40.8 months). In addition, the use of pertuzumab in combination with trastuzumab and docetaxel can increase the time to detection of brain metastases. The article also describes a clinical case of patient treated more than 60 months within the framework of the study.

Full Text

Restricted Access

References

  1. Cobleigh M.A., Vogel C.L., Tripathy D. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999;17:2639-48.
  2. Vogel C.L., Cobleigh M.A., Tripathy D. et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002;20:719-26.
  3. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001;344:783-92.
  4. Nahta R., Esteva F.J. HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006;8:215.
  5. Franklin M., Carey K., Vajdos F., et al. Insights into ErbB signaling from the structure of the ErbB2 pertuzumab complex. Cancer Cell. 2004;5:317-28.
  6. Corts J., et al. Pertuzumab monotherapy follow ing trastuzumab_based treatment: Activity and tolerability in patients with advanced HER2-positive breast cancer. ASCO. 2009;abstr. 1022.
  7. Baselga J, et al. Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. J. Clin. Oncol. 2010;28(7):1138-44.
  8. Baselga J, Cortes J., Kim S.-B., et al. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. The New England journal of medicine. 2012;366(2).
  9. Swain S.M., Kim., S.-B., et al. Pertuzumab, trastu zumab and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA STUDY): overall survival results from a randomized, doubleblind, placebo-controlled, phase 3 study. www. thelancet.com/oncology Published online April 18,2013.
  10. Swain S., Kim S.-B., Cortes J., et al. Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). ESMO. 2014:abstr. 3500 PR.
  11. Swain S.M., Kim S.-B., Corts J., et al. Final overall survival (OS) analysis from The CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients with HER2-positive metastatic breast cancer (MBC). Oral. Presentation, ESMO 2014.
  12. Swain S.M., Baselg J., Miles D., et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann. Oncol. 2014:25(6):1116-22.
  13. Lee Y.T. Breast carcinoma: Pattern of metastasis at autopsy. J. Surg. Oncol. 1983;23:175-80.
  14. Boogerd W., Vos V.W., Hart A.A., et al. Brain metastasis in breast cancer, natural history, prognostic factors and outcome. J. Neurooncol. 1993;15:165-74.
  15. Tsukada Y., Fouad A., Pickren J., et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52: 2349-54.
  16. Pinder M.C., Chang H., Broglio K.R., et al. Trastuzumab treatment and the risk of central nervous system (CNS) metastases. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. 2007;2:1018.
  17. Gabos Z., Sinha R., Hanson J., et al. Prognostic significance of human epidermal growth factor r ceptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J. Clin. Oncol 2006;24: 5658-63.
  18. Pestalozzi B.C., Zahrieh D., Price K.N., et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann. Oncol. 2006;17:935-44.
  19. Bendell J.C., Domchek S.M., Burstein H.J., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972-77.
  20. Heinrich B., Brudler O., Siekiera W., et al. Development of brain metastases in metastatic breast cancer (MBC) responding to treatment with trastuzumab. Proc Am. Soc. Clin. Oncol. 2003;22:37.
  21. Kirsch D.G., Ledezma C.J., Mathews C.S., et al. Survival after brain metastases from breast cancer in the trastuzumab era. J. Clin. Oncol. 2005;23:2114-16.
  22. Miles D., Baselga J., Amadori D., et al. Treatment of older patients with HER2-positive metastatic breastvcancer with pertuzumab, trastuzumab, and docetaxel: subgroupvanalyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res. Treat. 2013;142:89-99.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies